AstraZeneca’s Phase II SERD data raise hopes for the class

The rocky road for selective estrogen receptor degraders may have gotten a bit smoother Wednesday with a Phase II win for AstraZeneca’s camizestrant. 

The pharma has marketed the sole approved SERD, Faslodex fulvestrant, for two decades, and development of next-generation SERDs with improved properties has hit recent setbacks. ...